Derazantinib in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma



Status:Recruiting
Conditions:Liver Cancer, Liver Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/24/2019
Start Date:November 10, 2017
End Date:March 2021
Contact:Stephan Braun, MD
Email:stephan.braun@basilea.com
Phone:+41 61 606 12 25

Use our guide to learn which trials are right for you!

A Pivotal Trial of Derazantinib in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

This pivotal, open-label, single-arm study will evaluate the anti-cancer activity of
derazantinib by Objective Response Rate (ORR) by central radiology review as per RECIST v1.1
in subjects with inoperable or advanced intrahepatic cholangiocarcinoma (iCCA) whose tumors
harbor FGFR2 gene fusions (by FISH performed by the central laboratory) and who received at
least one prior regimen of systemic therapy. Subjects will be dosed orally once per day at
300 mg of derazantinib capsules.


Inclusion Criteria:

1. Signed written informed consent granted prior to initiation of any study-specific
procedures

2. 18 years of age or older

3. Histologically or cytologically confirmed locally advanced, inoperable (where surgery
is not indicated due to disease extension, co-morbidities, or other technical
reasons), or metastatic iCCA or mixed histology tumors (combined
hepatocellular-cholangiocarcinoma [cHCC-CCA])

4. FGFR2 gene fusion status based on the following assessments:

1. If central laboratory designated by Sponsor:

Positive FISH test; and/or

2. If non-central laboratory:

i) Positive FISH or NGS test: patients may be enrolled and may start dosing, but
central confirmation is required*

ii) Negative FISH or NGS test: tissue may be submitted to the central laboratory
designated by the Sponsor, and patients may only be enrolled if the central test is
positive

*Using standard protocols and approved by local IRB/EC, by CLIA or other similar
agency.

5. Received at least one regimen of prior systemic therapy and then experienced
documented radiographic progression or was not able to tolerate prior systemic
therapy.

- If the subject received at least 4 cycles of systemic therapy and no measurable
tumor reduction compared to the previous scan is observed, such subject can be
enrolled

- If the subject received immunotherapy, the documented radiographic disease
progression is required

6. Measurable disease by RECIST version 1.1 criteria

7. ECOG performance status ≤ 1

8. Adequate organ functions as indicated by the following laboratory values (based on
screening visit values from the central laboratory).

- Hematological

- Hemoglobin (Hgb) ≥ 9.0 g/dL

- Absolute neutrophil count (ANC) ≥ 1.5 x 109/L

- Platelet count ≥ 75 x 109/L

- International normalized ratio (INR) 0.8 to upper limit of normal (ULN) or ≤
3 for subjects receiving anticoagulant therapy such as Coumadin or heparin

- Hepatic

- Total bilirubin ≤ 2 x ULN

- AST and ALT ≤ 3 ULN (≤ 5 x ULN for subjects with liver metastases)

- Albumin ≥ 2.8 g/dL

- Renal

- Serum creatinine ≤ 1.5 x ULN

- Creatinine clearance of ≥ 60 mL/min as estimated by the Cockcroft-Gault
equation

9. Male or female subjects of child-producing potential must agree to use double-barrier
contraceptive measures, oral contraception, or avoidance of intercourse during the
study and for 90 days after the last dose of derazantinib

Exclusion Criteria:

1. Systemic anti-cancer therapy, such as chemotherapy, immunotherapy, hormonal, targeted
therapy, or investigational agents within four weeks of the first dose of derazantinib

2. Major surgery, locoregional therapy, or radiation therapy within four weeks of the
first dose of derazantinib

3. Previous treatment with any FGFR inhibitor (e.g., ponatinib, dovitinib, nintedanib,
AZD4547, NVP-BGJ398, LY2784455, BAY1163877)

- Subjects who received less than four weeks of therapy and were unable to continue
therapy due to toxicity will be allowed to participate

4. Unable or unwilling to swallow the complete daily dose of derazantinib capsules

5. Clinically unstable central nervous system (CNS) metastases (to be eligible, subjects
must have stable disease ≥ 3 months, confirmed by magnetic resonance imaging (MRI) or
computed tomography (CT) scan, and/or have CNS metastases well controlled by low-dose
steroids, anti-epileptics, or other symptom-relieving medications)

6. Current evidence of corneal or retinal disorder, including but not limited to
bullous/band keratopathy, keratoconjunctivitis, corneal abrasion,
inflammation/ulceration, confirmed by ophthalmologic examination

7. Concurrent uncontrolled or active hepatobiliary disorders, untreated or ongoing
complications after laparoscopic procedures or stent placement, including but not
limited to active cholangitis, biloma or abscess (to be eligible, the subjects have to
be treated and disorders/complications should be resolved within 2 weeks prior to the
first dose of derazantinib)

8. History of significant cardiac disorders:

- Myocardial infarction (MI) or congestive heart failure defined as Class II to IV
per the New York Heart Association (NYHA) classification within 6 months of the
first dose of derazantinib (MI that occurred > 6 months prior to the first dose
of derazantinib will be permitted)

- QTcF >500 msec (males or females)

9. Significant gastrointestinal disorder(s) that could, in the opinion of the
Investigator, interfere with the absorption, metabolism, or excretion of derazantinib
(e.g., Crohn's disease, ulcerative colitis, extensive gastric resection)

10. Previous malignancy within 2 years of the first dose of derazantinib, except
curatively treated or low grade malignancies such as non-melanoma skin cancer,
carcinoma in-situ of the breast, cervix, and superficial bladder tumors

11. Concurrent uncontrolled illness not related to cancer, including but not limited to:

- Psychiatric illness/substance abuse/social situation that would limit compliance
with study requirements

- Known uncontrolled human immunodeficiency virus (HIV) infection

12. Blood or albumin transfusion within 5 days of the blood draw being used to confirm
eligibility

13. Pregnant or breast feeding
We found this trial at
9
sites
Rochester, Minnesota 55905
Phone: 781-994-0300
?
mi
from
Rochester, MN
Click here to add this to my saved trials
4201 Belfort Road
Jacksonville, Florida 32216
(408) 293-2336
Phone: 781-994-0300
Mayo Clinic Mayo Clinic's campus in Arizona provides medical care for thousands of people from...
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
2220 Pierce Ave
Nashville, Tennessee 37232
615-936-8422
Phone: 781-994-0300
Vanderbilt-Ingram Cancer Center The Vanderbilt-Ingram Cancer Center, located in Nashville, Tenn., brings together the clinical...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
1365 Clifton Rd NE
Atlanta, Georgia 30322
(404) 778-1900
Phone: 781-994-0300
Winship Cancer Institute at Emory University Winship Cancer Institute of Emory University is Georgia
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Calgary, Alberta
Phone: 781-994-0300
?
mi
from
Calgary,
Click here to add this to my saved trials
1515 Holcombe Blvd
Houston, Texas 77030
 713-792-2121
Phone: 781-994-0300
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
?
mi
from
Houston, TX
Click here to add this to my saved trials
3400 Civic Center Blvd
Philadelphia, Pennsylvania 19104
(215) 662-6065
Phone: 781-994-0300
Abramson Cancer Center of the University of Pennsylvania The Abramson Cancer Center of the University...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
5777 East Mayo Boulevard
Phoenix, Arizona 85054
(480) 515-6296
Phone: 781-994-0300
Mayo Clinic Mayo Clinic's campus in Arizona provides medical care for thousands of people from...
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
1959 NE Pacific St
Seattle, Washington 98195
(206) 598-3300
Phone: 781-994-0300
University of Washington Medical Center University of Washington Medical Center is one of the nation's...
?
mi
from
Seattle, WA
Click here to add this to my saved trials